Novo Holdings optimistic about investments in life sciences
Novo Holdings is planning to increase its investment in early & late stage biotechs. Its focus will be mainly in the U.S. and Europe. They are optimistic about the investment in life-science companies with their past experience.
NMD gets USD 47 million for orphan neuromuscular disease trials
NMD Pharma has got USD 47 million for the trials of two orphan neuromuscular disease. This will be effective in knowing whether the outcomes seen in models of myasthenia gravis and amyotrophic lateral sclerosis translated into the clinic. NMD assumes that it will be applicable across wide conditions.
Ablynx lupus drug...
